Co-Diagnostics (CODX) Fireside Chat summary
Event summary combining transcript, slides, and related documents.
Fireside Chat summary
13 Nov, 2025Introduction and agenda
Discussion covered updates on diagnostics technology, company history, clinical pathway, commercialization, and recent announcements including a Saudi Arabia joint venture and AI initiatives.
The session included a live Q&A with audience participation and was recorded for later access.
Background and experience of the speaker
The company was founded in 2013, based on Co-Primers technology invented by Dr. Brent Satterfield.
The technology enables multiplex PCR testing, allowing detection of multiple indications in a single test.
Current industry trends
There is a global push to replace outdated diagnostic methods like smear microscopy with affordable molecular tests.
Artificial intelligence is increasingly integrated into diagnostics for improved accuracy and efficiency.
Latest events from Co-Diagnostics
- Q2 revenue up, net loss narrowed, and FDA 510(k) submission advances new PCR platform.CODX
Q2 20242 Feb 2026 - Q3 revenue fell to $641K, net loss widened, but diagnostics pipeline and cash remain strong.CODX
Q3 202415 Jan 2026 - 2024 revenue fell and net loss widened as regulatory and manufacturing efforts progressed.CODX
Q4 202426 Dec 2025 - Annual meeting to vote on director, executive pay, and auditor, with board recommending all proposals.CODX
Proxy Filing2 Dec 2025 - Proxy covers director elections, equity plan, executive pay, and auditor ratification.CODX
Proxy Filing2 Dec 2025 - Q2 2025 revenue fell, losses persisted, and clinical trials for four PCR tests remain on track.CODX
Q2 202523 Nov 2025 - Net loss narrowed to $7.5M as diagnostics pipeline advanced, but liquidity risks persist.CODX
Q1 202518 Nov 2025 - Revenue fell and losses narrowed, but MENA expansion and AI initiatives drive future growth.CODX
Q3 202517 Nov 2025 - Vote sought on a reverse stock split to maintain Nasdaq listing; Board recommends approval.CODX
Proxy Filing10 Nov 2025